New Zealand markets open in 36 minutes

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.9700-0.2300 (-10.45%)
At close: 04:00PM EDT
2.0000 +0.03 (+1.52%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.2000
Open2.2650
Bid2.0000 x 1000
Ask2.0100 x 4000
Day's range1.9200 - 2.4099
52-week range0.6800 - 19.8700
Volume41,542,091
Avg. volume6,821,674
Market cap69.083M
Beta (5Y monthly)1.87
PE ratio (TTM)N/A
EPS (TTM)-3.2550
Earnings date08 Nov 2022 - 14 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.25
  • Zacks

    Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

    The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

  • GlobeNewswire

    GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

    The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties. GSK to purchase $9 million in shares of Spero common stock LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agree

  • GlobeNewswire

    Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

    Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective productsCAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). “Kamal joins Spero with an impressive track record of building and leading successful anti-infective franchises,” said Ankit Mahadevia, MD, Chief Executive Officer o